Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | 283.26M +26.6% |
| Revenue (ttm) | 13.08M +19.9% |
| Net Income | -32.26M |
| EPS | -0.19 |
| Shares Out | 252.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 763,808 |
| Open | 1.130 |
| Previous Close | 1.130 |
| Day's Range | 1.095 - 1.148 |
| 52-Week Range | 0.970 - 2.090 |
| Beta | 1.55 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+391.07%) |
| Earnings Date | Aug 6, 2026 |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a... [Read more]
Financial Performance
In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 391.07% from the latest price.
News
Lineage Cell Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw continued pipeline progress, with OpRegen advancing under Roche, rapid development in COR1 and ILT1, and a shift to chronic SCI patients for OPC1. Cash runway extends into Q3 2028, with net income of $1.5 million driven by non-cash gains and disciplined expense management.
Lineage Cell Therapeutics Earnings release: Q2 2026
Lineage Cell Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lineage Cell Therapeutics Quarterly report: Q2 2026
Lineage Cell Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)
Reports Q2 revenue $1.069M, consensus $1.53M. “As we continue to support our collaboration with Roche and Genentech for their clinical development of OpRegen, Lineage remains focused on building out o...
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogenei...
Lineage Cell Therapeutics Transcript: Study update
COR1, an allogeneic cell therapy for corneal endothelial disease, leverages a proprietary scalable manufacturing platform to address the global shortage of donor corneas. The program emphasizes robust process development, high product quality, and cost-effective, minimally invasive delivery, with preclinical animal data expected this year.
Lineage Cell Therapeutics Press release: Study update
Lineage Cell Therapeutics issued a press release on July 13, 2026, disclosing material business information to investors.
Lineage Cell Therapeutics provides update on COR1 program
Lineage Cell provided an update on COR1, the Company’s allogeneic corneal endothelial cell transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, L...
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogenei...
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” ...
Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)
Reports Q1 revenue $1.73M, consensus $3.6M. “This quarter, we continued to build on our developmental and clinical accomplishments. Most notably, we applied our proprietary cell manufacturing technolo...
Lineage Cell Therapeutics Earnings Call Transcript: Q1 2026
Expanded cell therapy pipeline with new programs in ophthalmology and diabetes, robust manufacturing advances, and strong cash position. OpRegen continues to show promise as a disease-modifying treatment, with multiple clinical and partnership milestones anticipated in 2026.
Lineage Cell Therapeutics Earnings release: Q1 2026
Lineage Cell Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Lineage Cell Therapeutics Quarterly report: Q1 2026
Lineage Cell Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” ...
Lineage Cell Therapeutics Slides: Corporate presentation
Lineage Cell Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” ...
Lineage Cell announces 36-month results from Phase 1/2a study of RG6501
Lineage Cell Therapeutics (LCTX) announced that 36-month results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular de...
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” ...
Lineage Cell Therapeutics Proxy statement: Proxy filing
Lineage Cell Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Lineage Cell Therapeutics Proxy statement: Proxy filing
Lineage Cell Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Lineage Cell Therapeutics initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $9 price target The firm expects Roche to proceed with clinical studies for Lineage’s…
Lineage Cell Therapeutics announces formation of Scientific Advisory Board
Lineage Cell Therapeutics (LCTX) announced the formation of a Scientific Advisory Board, SAB, to provide strategic counsel and insights into the development of Lineage’s novel cell transplant pipeline...
Lineage Announces Formation of Scientific Advisory Board
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...